Get started
AB Science SAAB Science SAAB Science SA

AB Science SA

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonals

Documents


Explore the latest documents from the company, including regulatory filings and corporate disclosures that offer insight into company performance and strategy. Use these resources to support informed investment decisions.
2025
Earnings, H2 FY2025
Annual
May 13, 2026
Net loss fell 80% year-over-year as clinical focus narrowed to ALS and AML, with improved cash and financing.
Status Update
Oct 16, 2025
AB8939 demonstrates strong early efficacy in ultra high-risk AML, advancing to pivotal trials.
Earnings, H1 FY2025
Oct 10, 2025
Operating deficit fell 24% year-over-year; key clinical and patent milestones achieved.
Status Update
Jan 28, 2025
Masitinib advances in neurodegenerative diseases with new confirmatory trials and strong market potential.
2024
Earnings, H2 FY2024
Annual
May 9, 2025
Operating loss halved and cash bolstered as clinical pipeline advances and IP portfolio grows.
Status Update
Dec 16, 2024
AB8939 demonstrates promising efficacy in refractory and MECOM AML, with Phase II trials planned.
Earnings, H1 FY2024
Oct 10, 2024
Operating deficit and net loss dropped significantly, with regulatory reviews and new capital raised.
Status Update
May 30, 2024
Status Update
Mar 4, 2024
2023
Earnings, H2 FY2023
Annual
May 15, 2024
Status Update
Nov 30, 2023
Earnings, H1 FY2023
Sep 29, 2023
Status Update
Mar 16, 2023
2022
Earnings, H2 FY2022
Annual
Apr 28, 2023
Earnings, H1 FY2022
Sep 30, 2022
Status Update
Feb 28, 2022
2021
Earnings, H2 FY2021
Annual
Apr 28, 2022
Earnings, H1 FY2021
Sep 30, 2021
2020
Earnings, H2 FY2020
Annual
Apr 30, 2021
2019
Earnings, H2 FY2019
Annual
Apr 30, 2020
2018
Earnings, H2 FY2018
Annual
Apr 30, 2019
2017
Earnings, H2 FY2017
Annual
Apr 30, 2018
2016
Earnings, H2 FY2016
Annual
Apr 30, 2017
2015
Earnings, H2 FY2015
Annual
Apr 28, 2016